Global Biopharmaceutical Bioseparation Systems Industry

Global Biopharmaceutical Bioseparation Systems Industry

  • April 2021 •
  • 193 pages •
  • Report ID: 3646060 •
  • Format: PDF
Abstract:
- Global Biopharmaceutical Bioseparation Systems Market to Reach $12.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Biopharmaceutical Bioseparation Systems estimated at US$7.1 Billion in the year 2020, is projected to reach a revised size of US$12.6 Billion by 2027, growing at aCAGR of 8.4% over the period 2020-2027. Chromatography, one of the segments analyzed in the report, is projected to record 8% CAGR and reach US$6.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Other Technologies segment is readjusted to a revised 8.8% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 12.6% CAGR
- The Biopharmaceutical Bioseparation Systems market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2027 trailing a CAGR of 12.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

- Select Competitors (Total 55 Featured) -
  • 3M Purification Inc.
  • Agilent Technologies, Inc.
  • Alfa Wassermann Separation Technologies LLC
  • Flottweg Separation Technology
  • GE Healthcare Life Sciences
  • GEA Westfalia Separator Group GmbH
  • KNAUER Wissenschaftliche Geräte GmbH
  • Konik Nanobiotech SL
  • Merck KGaA
  • Pall Corporation
  • ProMetic Life Sciences Inc.
  • Repligen Corp.
  • Sartorius Stedim Biotech
  • Thermo Fischer Scientific Inc.
  • Tosoh Bioscience Inc.
  • YMC Europe GMBH